{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T22:31:35Z","timestamp":1787524295770,"version":"build-2736575974"},"reference-count":14,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,8,2]],"date-time":"2005-08-02T00:00:00Z","timestamp":1122940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Levetiracetam is a new antiepileptic agent that exerts antimyoclonic effects. We conducted an open\u2010label trial to evaluate the effect of levetiracetam in chronic cortical myoclonus of diverse etiologies and to determine whether levetiracetam affects electrophysiological findings. Sixteen patients, aged between 19 and 72 years, with refractory, chronic, cortical myoclonus were recruited. We assessed myoclonus severity with the Unified Myoclonus Rating Scale (UMRS). The electrophysiological study comprised jerk\u2010locked averaging, somatosensory evoked potentials (SEPs), and long loop reflex I. Levetiracetam was administered add\u2010on at a starting dose of 500 mg twice per day up to the target dose of 50 mg\/kg\/day. Patients were reevaluated clinically and electrophysiologically 2 weeks after the titration phase. Fourteen patients completed the trial. Posttreatment UMRS scores showed an improvement of myoclonus in all cases. Pretreatment, 9 patients had \u201cgiant\u201d SEPs. Posttreatment, the amplitude of these SEPs was reduced by more than 50% in 3 of 9 patients, and the mean N20\u2010P25 amplitude was reduced significantly. Pre\u2010 and posttreatment SEP amplitude was not related to myoclonus severity or duration. Levetiracetam is a promising and a relatively easy\u2010to\u2010test antimyoclonic agent, which has the potential to improve significantly the patient's disability; however, its long\u2010term efficacy should be verified in larger controlled studies. \u00a9 2005 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.20530","type":"journal-article","created":{"date-parts":[[2005,8,3]],"date-time":"2005-08-03T16:26:17Z","timestamp":1123086377000},"page":"1610-1614","source":"Crossref","is-referenced-by-count":56,"title":["Levetiracetam in patients with cortical myoclonus: A clinical and electrophysiological study"],"prefix":"10.1002","volume":"20","author":[{"given":"Pasquale","family":"Striano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiore","family":"Manganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Boccella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Perretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,8,2]]},"reference":[{"key":"e_1_2_6_2_2","series-title":"Myoclonus and paroxysmal dyskinesias. Advances in Neurology","author":"Frucht SJ","year":"2002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110615"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.5.781"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.6.1112"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110193.78872.DD"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.56902.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01225.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055874.24000.4A"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/108.1.225"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.24501.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.02141.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.3.411"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198812000-00006"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.20530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.20530","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.20530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:17:44Z","timestamp":1760959064000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.20530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,2]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1002\/mds.20530"],"URL":"https:\/\/doi.org\/10.1002\/mds.20530","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,2]]}}}